ao biokimik

What ao biokimik does

АО «Биохимик» (AO Biochemik) is a Russian full-cycle pharmaceutical manufacturer headquartered in Saransk, Republic of Mordovia, and operating as the primary production arm of the publicly listed Promomed Group (ПАО «ПРОМОМЕД», Moscow Exchange). The company runs an integrated value chain spanning its own Research & Development Hub, clinical development, active pharmaceutical ingredient manufacturing, and finished-dose production across two manufacturing sites (Saransk and Obninsk). Its commercial portfolio exceeds 360 drugs spanning oncology, endocrinology, neurology, infectious diseases, musculoskeletal disorders, and general therapy, with over 60% of products included in Russia's vital and essential medicines list (VNIILP). The portfolio combines generic reproductions with original drugs developed in-house, most notably the COVID-19 antivirals Skyvira (nirmatrelvir/ritonavir) and Esperavir (molnupiravir), as well as the neurological franchise Brainmax (meldonium + ethylmethylhydroxypyridine succinate) and the musculoskeletal franchise Ambene Bio / Ambene Chondro.

The business model is wholesale B2B pharmaceutical distribution: products reach patients through direct institutional sales to hospitals and clinics and through a broad network of Russian retail pharmacy chains (Apteka.ru, Zdravsiti, Rigla, Planeta Zdorovya, 36.6, Magnit Pharmacy, ASNA, and others). Pricing is not publicly disclosed; revenue derives from one-time product sales of prescription and OTC pharmaceuticals. The company holds registration certificates as manufacturer of record for original drugs and ranks No. 1 in Russia by number of medical research studies (IQVIA 2022-2024). It is currently expanding into endocrinology (tirzepatide-based research), hepatology (new dual-action hepatoprotector launched August 2025), and into CIS and Southeast Asian markets via offices in Tashkent, Almaty, and Ho Chi Minh City, while pursuing label extensions for existing molecules such as molnupiravir in influenza/ARVI.

Strategically, Biohimik operates within the Promomed Group's broader portfolio; group leadership includes Pyotr Belyy as Chairman and Alexander Efremov as General Director. The Biohimik entity itself employs 2,000+ people at Saransk, with 3,000+ group-wide and 200+ PhDs and candidates of sciences across the group. No standalone revenue figure for Biohimik is publicly disclosed in the source material, and the subsidiary has no independent public listing, although its parent is publicly traded on Moscow Exchange.

Name

ao biokimik

Legal name

АО «Биохимик»

Website

https://biohimik.ru

Company type

Private

Founded year

1959

Operating status

Operating

Short description

АО «Биохимик» is a Russian full-cycle pharmaceutical manufacturer based in Saransk, producing over 360 original and generic drugs across COVID-19 antivirals, oncology, neurology, and musculoskeletal areas for distribution through Russian pharmacy chains and hospital procurement as the primary manufacturing arm of Promomed Group.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Generic drug production
• Antiviral therapeutics
• Chondroprotective medications

Headquarters

HQ city

Saransk

HQ country

Russia

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical product sales: Sale of prescription and OTC pharmaceutical products across therapeutic areas including oncology, endocrinology, neurology, general therapy, and anti-infectives. Revenue generated through direct institutional sales and pharmacy distribution network.

Go-to-market motion2 records

Distribution channels7 records

Marketing channels3 records

Core offering

AO Biochemik is a Russian pharmaceutical manufacturer that produces active pharmaceutical ingredients and finished dosage forms including original and generic drugs. The company manufactures COVID-19 antivirals (Skyvira with nirmatrelvir/ritonavir, Esperavir with molnupiravir), neurological drugs (Brainmax), and chondroprotective medications (Ambene Bio, Ambene Chondro) at its Saransk facility under the Promomed Group.

Product overview

АО «Биохимик» (ao biokimik) is a biopharmaceutical company and part of the ПРОМОМЕД Group. The company manufactures a portfolio of original pharmaceutical products including antiviral drugs (Скайвира® with nirmatrelvir/ritonavir, Эсперавир® with molnupiravir), neurological drugs (Брейнмакс® in capsule and solution forms), and chondroprotective medications (Амбене® Био solution and Амбене® Хондро capsules). The products are manufactured at the company's facility in Saransk, Mordovia, Russia, and distributed through various pharmacy chains. The portfolio covers therapeutic areas including infectious diseases (COVID-19), neurology, and musculoskeletal disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• Skyvira (Скайвира) Original antiviral drug containing nirmatrelvir 300mg + ritonavir 100mg (ATX code J05AE30) used for treatment of COVID-19 in adults with mild or moderate severity. Registration holder: AO Biochemik, Saransk, Mordovia.
• Esperavir (Эсперавир) Antiviral drug containing molnupiravir (200mg or 400mg capsules, ATX code J05AB18) for treatment of COVID-19 in adults. Active substance metabolizes to N-hydroxycytidine analog, acting through viral replication error catastrophe mechanism.
• Brainmax Capsules (Брейнмакс) Neurological drug combining meldonium and ethylmethylhydroxypyridine succinate (250mg + 250mg per capsule). Used for cerebrovascular insufficiency, cognitive impairments, reduced performance, mental and physical overstrain. Activates metabolic processes and improves brain microcirculation.
• Brainmax Solution (Брейнмакс) Solution for intravenous and intramuscular administration containing meldonium and ethylmethylhydroxypyridine succinate (100mg/ml + 100mg/ml). Used for acute and chronic cerebral circulation disorders including ischemic stroke, dyscirculatory encephalopathy, and cognitive disorders.
• Ambene Bio (Амбене Био) Chondroprotective solution for injection containing bioactive extract from small marine fish. Used for primary and secondary osteoarthrosis of various localization, osteochondrosis, and spondylosis. Prevents destruction of macromolecular structures and stimulates restoration of interstitial tissue and articular cartilage.
• Ambene Chondro (Амбене Хондро) Chondroprotective capsules containing chondroitin sulfate (250mg or 500mg). Used for degenerative diseases of joints and spine (osteoarthrosis, osteochondrosis). Affects metabolic processes in hyaline and fibrous cartilage, stimulates glycosaminoglycan biosynthesis.

Quantifiable outcome

• No. 1 in Russia by number of medical research studies (IQVIA 2022-2024)
• +1 more outcomes

Named customers7 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Morduvin State University (N.P. Ogarev)coreStrategic or Co-development PartnerEducational partnership with established chemistry and pharmaceutical technology department. Company supports laboratory facilities and contributes to pharmaceutical workforce development.
• Russian University of Medicine (N.A. Semashko)coreStrategic or Co-development PartnerAcademic partnership for clinical research and medical education. Pro-rector Professor Igor Maev serves as board member, contributing expertise in gastroenterology and clinical medicine.
• Pharmacy Distribution NetworkcoreChannel Partner/ Reseller/ DistributorExtensive network of pharmacy partners including Apteka.ru, Zdravsiti, Rigla, April, Planeta Zdorovya, 36.6, Farmlend, ASNA, Vita, and others for OTC product distribution.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Pharmstandard: Largest Russian pharmaceutical manufacturer by revenue with a broad generic and original drug portfolio across multiple therapeutic areas. Highly comparable in scale, business model (R&D + manufacturing + pharmacy distribution) and reliance on Russian domestic demand.
• R-Pharm: Vertically integrated Russian pharma company with own R&D, manufacturing of original and generic drugs (including COVID antivirals and oncology products). Direct competitor for hospital tenders and VNIILP-listed products.
• Vertex: St. Petersburg-based Russian pharmaceutical manufacturer producing generic and branded drugs across therapeutic categories. Comparable in scale, GTM motion (pharmacy chains + hospital sales) and product mix.
• Valenta Pharm: Russian pharmaceutical manufacturer focused on original and generic drugs in neurology, immunology and infectious diseases. Direct competitor in several overlapping therapeutic areas and pharmacy-channel GTM.
• Geropharm: St. Petersburg-based Russian pharma with endocrinology, neurology and infectious disease focus; manufactures insulin and peptide drugs. Comparable as a domestic original-drug developer competing for VNIILP-listed slots.

Emerging players

• NovaMedica: Russian pharmaceutical company developing and commercializing innovative drugs, partly in partnership with global pharma. Comparable as a domestic original-drug developer in overlapping therapeutic areas.

Regional players

• KRKA: Slovenian generic manufacturer with a substantial Russian commercial footprint (one of the top foreign generic players in Russia). Comparable as a generic-and-branded manufacturer selling into the same Russian pharmacy channel.
• STADA: European generics and specialty pharma with significant CIS/Russia operations. Comparable business model (generic + branded generics) and pharmacy distribution into the same retail networks.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ao biokimik